The others segment by type is estimated to lead the market growth during the forecast period.

Technological developments in the pharmaceutical industry led to drastic evolution and better treatment. The pharmaceutical industry has incorporated intelligent technologies such as deep learning, artificial intelligence (AI), and machine learning to develop new antibiotics. Researchers are working to establish tools and platforms for identifying new antibiotics. It is expected that the novel technologies in new antibiotic discoveries are supposed to change the overall antibiotics market. However, developing antibiotics for gram-negative bacteria is challenging, as various drugs are still developing.

The major challenge for the development of antibiotics is the limited permeability of molecules across the bacterial envelope. However, gram-negative bacteria have nutrient-specific protein channels (porins) that restrict the permeability of non-essential molecules, including antibiotics. Permeability has allowed researchers to develop a new platform called computational antibiotic screening (CLASP), which helps identify potential drug molecules through porins.

CLASP has the advantage of coarse grain (CG) resolution, advanced sampling techniques, and a parallel computing environment that maximizes its performance. It provides complete thermodynamic and kinetic results of a potential drug molecule under study in a few hours. It helps in understanding or identifying small molecule libraries that yield structure-property relationships to discover antibiotics with high permeability. Thus, it is expected that CLASP will accelerate the new antibiotic drug for gram-negative bacterial infections, thus further leading to significant market growth.

Also, generic versions are popular due to their availability and affordability. In addition, the expiry of patented carbapenem-based antibiotics has widen-up opportunities for generic drug manufacturers to enter the market with their cost-efficient drugs. As a result, companies are accelerating generic drug production and driving the Middle East carbapenem-based antibiotics market.

The Middle East and Africa carbapenem-based antibiotics market, by type, is segmented into meropenem, doripenem, imipenem, tebipenem, and others. Based on indication, the Middle East and Africa carbapenem-based antibiotics market has been segmented into bacterial meningitis, acute pelvic infections, respiratory tract infections, intra-abdominal infections, urinary tract infections, and others. Based on distribution channel, the Middle East and Africa carbapenem-based antibiotics market has been segmented into retail pharmacies, online pharmacies, and hospital pharmacies. Geographically, the Middle East and Africa carbapenem-based antibiotics market is sub-segmented into UAE, Saudi Arabia, South Africa and Rest of MEA.

ACS Dobfar S.p.A, Aurobindo Pharma Ltd, DAEWOONG PHARMACEUTICAL CO., LTD, Gland Pharma Limited, Merck & Co., Inc., Sumitomo Dainippon Pharma Co., Ltd., Savior Lifetec, Pfizer Inc., and Spero Therapeutics are among the leading companies operating in the Middle East and Africa carbapenem-based antibiotics market.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com